1-ethyl-N-[3-(4-morpholinyl)propyl]-2-oxo-6-benzo[cd]indolesulfonamide is a complex organic compound with a long and unwieldy name. It's more commonly known by its abbreviation: **BMS-741718**.
**Why is BMS-741718 important for research?**
BMS-741718 is a potent and selective **inhibitor of the enzyme dihydrofolate reductase (DHFR)**. DHFR is an essential enzyme involved in the synthesis of tetrahydrofolic acid (THF), a crucial cofactor for many metabolic processes.
**Here's why inhibiting DHFR is important:**
* **Antibacterial and Anticancer Activity:** DHFR inhibition disrupts the folate metabolism pathway, which is crucial for DNA synthesis and cell proliferation. This makes DHFR inhibitors like BMS-741718 potential candidates for the development of:
* **Antibacterial drugs:** By targeting bacterial DHFR, you can inhibit their growth and potentially treat infections.
* **Anticancer drugs:** By interfering with DNA synthesis, you can slow down or halt the uncontrolled growth of cancer cells.
* **Research Tool:** BMS-741718 has been used as a valuable research tool to study:
* **The role of DHFR in different biological processes.**
* **The mechanism of action of DHFR inhibitors.**
* **The development of new and improved DHFR inhibitors.**
**Important Note:**
While BMS-741718 has shown promising results in preclinical studies, it's crucial to remember that:
* **It's not currently approved for any medical use.**
* **Further research is needed to evaluate its safety and efficacy in humans.**
If you have any further questions about BMS-741718 or its potential applications, please feel free to ask.
ID Source | ID |
---|---|
PubMed CID | 1582019 |
CHEMBL ID | 1304365 |
CHEBI ID | 123157 |
SCHEMBL ID | 16866314 |
Synonym |
---|
MLS000094943 |
smr000030497 |
AKOS000808608 |
CHEMBL1304365 |
HMS2376N13 |
1-ethyl-n-[3-(4-morpholinyl)propyl]-2-oxo-6-benzo[cd]indolesulfonamide |
Q27212662 |
STL487079 |
1-ethyl-n-[3-(morpholin-4-yl)propyl]-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide |
sr-01000104189 |
SR-01000104189-1 |
SCHEMBL16866314 |
CHEBI:123157 |
Z56842571 |
1-ethyl-n-(3-morpholin-4-ylpropyl)-2-oxobenzo[cd]indole-6-sulfonamide |
438479-43-7 |
Class | Description |
---|---|
naphthalenes | Any benzenoid aromatic compound having a skeleton composed of two ortho-fused benzene rings. |
sulfonic acid derivative | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, HADH2 protein | Homo sapiens (human) | Potency | 31.6228 | 0.0251 | 20.2376 | 39.8107 | AID893 |
Chain B, HADH2 protein | Homo sapiens (human) | Potency | 31.6228 | 0.0251 | 20.2376 | 39.8107 | AID893 |
Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 25.1189 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 31.6228 | 5.6234 | 17.2929 | 31.6228 | AID485281 |
acid sphingomyelinase | Homo sapiens (human) | Potency | 25.1189 | 14.1254 | 24.0613 | 39.8107 | AID504937 |
ClpP | Bacillus subtilis | Potency | 28.1838 | 1.9953 | 22.6730 | 39.8107 | AID651965 |
ATAD5 protein, partial | Homo sapiens (human) | Potency | 16.3601 | 0.0041 | 10.8903 | 31.5287 | AID504467 |
TDP1 protein | Homo sapiens (human) | Potency | 9.2000 | 0.0008 | 11.3822 | 44.6684 | AID686979 |
aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 25.1189 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
chromobox protein homolog 1 | Homo sapiens (human) | Potency | 89.1251 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
importin subunit beta-1 isoform 1 | Homo sapiens (human) | Potency | 71.9124 | 5.8048 | 36.1306 | 65.1308 | AID540253; AID540263 |
snurportin-1 | Homo sapiens (human) | Potency | 71.9124 | 5.8048 | 36.1306 | 65.1308 | AID540253; AID540263 |
GTP-binding nuclear protein Ran isoform 1 | Homo sapiens (human) | Potency | 31.6228 | 5.8048 | 16.9962 | 25.9290 | AID540253 |
muscleblind-like protein 1 isoform 1 | Homo sapiens (human) | Potency | 17.7828 | 0.0041 | 9.9625 | 28.1838 | AID2675 |
caspase-1 isoform alpha precursor | Homo sapiens (human) | Potency | 15.8489 | 0.0003 | 11.4484 | 31.6228 | AID900 |
Caspase-7 | Homo sapiens (human) | Potency | 15.8489 | 3.9811 | 18.5856 | 31.6228 | AID889 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Process | via Protein(s) | Taxonomy |
---|---|---|
RNA binding | Caspase-7 | Homo sapiens (human) |
aspartic-type endopeptidase activity | Caspase-7 | Homo sapiens (human) |
cysteine-type endopeptidase activity | Caspase-7 | Homo sapiens (human) |
protein binding | Caspase-7 | Homo sapiens (human) |
peptidase activity | Caspase-7 | Homo sapiens (human) |
cysteine-type peptidase activity | Caspase-7 | Homo sapiens (human) |
cysteine-type endopeptidase activity involved in apoptotic process | Caspase-7 | Homo sapiens (human) |
cysteine-type endopeptidase activity involved in execution phase of apoptosis | Caspase-7 | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Process | via Protein(s) | Taxonomy |
---|---|---|
extracellular space | Caspase-7 | Homo sapiens (human) |
nucleus | Caspase-7 | Homo sapiens (human) |
cytoplasm | Caspase-7 | Homo sapiens (human) |
cytosol | Caspase-7 | Homo sapiens (human) |
nucleus | Caspase-7 | Homo sapiens (human) |
nucleoplasm | Caspase-7 | Homo sapiens (human) |
cytosol | Caspase-7 | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID1127098 | Antagonist activity at Gal4-fused RORgamma (unknown origin) expressed in 293T cells at 10 uM after 24 hrs by luciferase reporter gene assay relative to control | 2014 | European journal of medicinal chemistry, May-06, Volume: 78 | Discovery of 2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide derivatives as new RORĪ³ inhibitors using virtual screening, synthesis and biological evaluation. |
AID1127099 | Antagonist activity at full-length RORgamma (unknown origin) expressed in 293T cells at 10 uM after 24 hrs by luciferase reporter gene assay relative to control | 2014 | European journal of medicinal chemistry, May-06, Volume: 78 | Discovery of 2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide derivatives as new RORĪ³ inhibitors using virtual screening, synthesis and biological evaluation. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (16.67) | 29.6817 |
2010's | 4 (66.67) | 24.3611 |
2020's | 1 (16.67) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.35) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |